Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$11.03
-3.1%
$12.17
$6.25
$19.22
$308.73M0.92261,326 shs289,669 shs
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$41.57
-2.1%
$39.04
$26.56
$50.85
$1.20B0.8474,569 shs264,078 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.11
$4.65
$13.13
$1.10B1.471.18 million shs19.38 million shs
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14.54
-0.4%
$14.88
$8.26
$19.41
$1.24B-0.011.30 million shs1.69 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
+0.44%-4.85%+1.88%-7.03%+56.97%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-2.77%-7.66%+13.47%+34.98%-10.67%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.08%+54.00%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
+2.89%+3.18%+7.43%+6.41%+28.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.7146 of 5 stars
3.51.00.00.01.90.80.6
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.2046 of 5 stars
3.41.00.00.02.12.50.6
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.248 of 5 stars
4.50.00.00.01.84.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$25.00126.65% Upside
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.83
Moderate Buy$54.8331.91% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.00
Buy$26.8984.93% Upside

Current Analyst Ratings Breakdown

Latest CLPT, ESTA, LQDA, and FNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.00
7/9/2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.00
6/13/2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$48.00
6/12/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.00
6/11/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $23.00
6/2/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $35.00
5/27/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$31.39M9.84N/AN/A$0.92 per share11.99
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$166.02M7.24N/AN/A$1.90 per share21.88
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14M88.79N/AN/A$0.91 per share15.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)

Latest CLPT, ESTA, LQDA, and FNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.20N/AN/AN/A$9.20 millionN/A
8/6/2025Q2 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.43N/AN/AN/A$3.90 millionN/A
8/5/2025Q2 2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.54N/AN/AN/A$50.80 millionN/A
5/13/2025Q1 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million
5/8/2025Q1 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/7/2025Q1 2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/A
3.53
2.57
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
5.72
3.36
2.05
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
2.08
2.93
2.91

Institutional Ownership

CompanyInstitutional Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
72.91%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
64.54%

Insider Ownership

CompanyInsider Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.97%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
11.09%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
26.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11027.99 million26.04 millionOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1,01828.92 million25.71 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
5085.49 million62.83 millionOptionable

Recent News About These Companies

Liquidia gets $50M more after first sale of Yutrepia to treat PH
What Next For Liquidia After Launch?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$11.03 -0.35 (-3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$11.04 +0.01 (+0.09%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Establishment Labs stock logo

Establishment Labs NASDAQ:ESTA

$41.57 -0.88 (-2.07%)
Closing price 04:00 PM Eastern
Extended Trading
$41.67 +0.10 (+0.24%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Liquidia Technologies stock logo

Liquidia Technologies NASDAQ:LQDA

$14.54 -0.06 (-0.41%)
Closing price 04:00 PM Eastern
Extended Trading
$14.54 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.